Compare Abeona Therapeutics Inc (ABEO) vs US Global Jets ETF (JETS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs US Global Jets ETF — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while US Global Jets ETF trades at $31.67. Which is the better fit depends on your goals.
| ABEO | JETS | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $33.34 |
52-Week Low | $4.17 | $23.12 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JETS trades at $33.34, up 0.42% with a bullish technical outlook from moving averages but overbought RSI signals. The ETF faces headwinds from soaring airline fuel costs, which jumped 85% in May to $6.7 billion (Reuters, 2026-07-07), pressuring profitability across the sector. Recent news highlights industry challenges including engine maker delays and fare pressures, though falling oil prices offer some relief.
Outlook remains cautious due to cyclical risks and fuel volatility; the ETF provides diversified airline exposure but requires monitoring of margin compression. Investment opportunity hinges on oil price trends and travel demand recovery, with significant downside risk if cost pressures persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
